Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 26, 2026Journal of Clinical MedicineOpen Access

Simultaneous Quantification of Multiple Immune Checkpoint Interactions in Melanoma

View Full Paper
Ask AI
Bookmark
Share

Authors

CCCristina Cacho-NavasLCLaura CamachoJAJon Agüero

Discussion

Loading...

Member takes

Overview

Randomized trial demonstrates relationships between immune checkpoints influencing survival in melanoma.

Key Points

  • The study aims to quantify multiple immune checkpoint interactions and assess their potential as biomarkers in melanoma treatment.
  • Applied amplified FRET-FLIM (QF-Pro®) technology for quantification of immune checkpoint interactions.
  • Analyzed FFPE tumour samples from melanoma patients treated with immune checkpoint inhibitors.
  • Conducted survival analysis based on immune interaction levels.
  • Quantified PD-1/PD-L1, CTLA-4/CD80, TIGIT/CD155, and LAG-3/MHC-II interactions in FFPE samples.
  • Patients with high PD-1/PD-L1 interactions also showed elevated CTLA-4/CD80 interactions.
  • High LAG-3/MHC-II interactions correlated with improved overall survival trend (p-value not specified).

Cite This Study

Cacho-Navas et al. (2026) studied this question.

synapsesocial.com/papers/6a65a337d3aea3239cd76747https://doi.org/10.3390/jcm15155771
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Predicting Response to Immune Checkpoint Inhibitors in Melanoma: Emerging Approaches in Digital Pathology, Spatial Profiling and Machine Learning2026
  2. 2Detection of tumor immune checkpoints: from pathological analysis to functional imaging2025 · 5 citations
  3. 3Abstract 6397: Immune profiling for improving responsiveness to ipilimumab plus nivolumab checkpoint blockade treatment in patients with metastatic melanoma2024
  4. 4Immune Checkpoint Inhibitors in Malignant Melanoma: Anti-PD-1, Anti-CTLA-4 and Anti-LAG-3 Therapies2026 · 3 citations
  5. 5Abstract 1218: Development of a proximity ligation-imaging mass cytometry platform for spatially resolved immune checkpoint analysis.2026